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Abstract
Background: Low intake of fish, polyunsaturated fatty acids (PUFA) and vitamin D deficiency has been suggested to 
play a role in the development of schizophrenia. Our aim was to evaluate the association between the intake of 
different fish species, PUFA and vitamin D and the prevalence of psychotic-like symptoms in a population-based study 
among Swedish women.
Methods: Dietary intake was estimated using a food frequency questionnaire among 33 623 women aged 30-49 years 
at enrolment (1991/92). Information on psychotic-like symptoms was derived from a follow-up questionnaire in the 
years 2002/03. Participants were classified into three predefined levels: low, middle and high frequency of symptoms. 
The association between diet and psychotic-like symptoms was summarized in terms of relative risks (RR) and 
corresponding 95% confidence intervals and was evaluated by energy-adjusted multinomial logistic regression.
Results: 18 411 women were classified as having a low level of psychotic-like symptoms, 14 395 as middle and 817 as 
having a high level. The risk of high level symptoms was 53% (95% CI, 30-69%) lower among women who ate fish 3-4 
times per week compared to women who never ate fish. The risk was also lower for women with a high intake of 
omega-3 and omega-6 PUFA compared to women with a lower intake of these fatty acids. The effect was most 
pronounced for omega-6 PUFAs. The RR comparing the highest to the lowest quartile of omega-6 PUFAs intake was 
0.78 (95% CI, 0.64-0.97). The associations were J-shaped with the strongest reduced risk for an intermediate intake of 
fish or PUFA. For fatty fish (herring/mackerel, salmon-type fish), the strongest inverse association was found for an 
intermediate intake (RR: 0.81, 95% CI, 0.66-0.98), whereas a high intake of fatty fish was associated with an increased risk 
of psychotic-like symptoms (RR: 1.90, 95% CI, 1.34-2.70). Women in the highest compared with the lowest quartile of 
vitamin D consumption experienced a 37% (95% CI, 22-50%) lower risk of psychotic-like symptoms.
Conclusion: Our findings raise a possibility that adult women with a high intake of fish, omega-3 or omega-6 PUFA and 
vitamin D have a lower rate of psychotic-like symptoms.
Background
Even though psychoses are relatively rare, between 5-15%
of the general population has been estimated to report
single schizophrenia-like symptoms like delusions, magi-
cal thinking, and hearing internal voices at some point in
their lifetime [1-3]. The biological mechanisms underly-
ing the etiology of schizophrenia and psychotic symp-
toms are largely unknown. Genetic constitution is
important [4], but environmental factors like an
unhealthy lifestyle with a poor diet may be involved [5,6].
Schizophrenia in adulthood is often preceded by milder
symptoms and delusions during adolescence. The typical
age of onset for schizophrenia is early adulthood (20-25
years of age). Expression of psychotic symptoms in popu-
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Page 2 of 13lations is continuous and characterized by differing levels
of severity and persistence [7]. Meta-analysis [8] and pro-
spective follow-up studies indicates that up to 75-90% of
developmental psychotic experiences are transitory. Per-
sistence and clinical relevant impairment may be related
to a family history of schizophrenia and environmental
risk factors that might interact with the genetic risk. Self-
reported psychotic experiences in the general population
may represent the developmental expression of popula-
tion genetic risk for psychosis [9].
Low maternal fish and seafood consumption during
pregnancy is reported to increase the risk for a low IQ
and suboptimal neuro-developmental outcomes in child-
hood [10], factors that in turn are associated with an
increased risk for adult mental disorders like schizophre-
nia [11]. A recent meta-analysis found a latitude related
increase in schizophrenia prevalence that was greater for
groups with low fish consumption [12]. Fatty fish is a rich
dietary source of essential fatty acids and vitamin D, both
of which could be implicated in the development of
schizophrenia.
For instance, it has been proposed that aberration in
metabolism of phospholipids could be a biochemical
basis for psychiatric disorders [13]. Neuronal membranes
are largely made up of phospholipids, and the brain phos-
pholipids are rich in polyunsaturated fatty acids (PUFA).
The main groups of PUFA are omega-6 and omega-3 fatty
acids, of which some need to be supplied through the
diet. Eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) belong to the omega-3 family, and are mainly
found in fatty fish. Although, only hypothesis generating,
two ecological studies support the hypothesis by report-
ing the ratio of saturated fat to PUFA in the diet is a
strong predictor of schizophrenia outcome, measured as
according to either clinical or to social variables [6,14].
Also, the dietary intake of PUFA was negatively corre-
lated with the severity of psychotic symptoms in patients
with schizophrenia [15]. Lower levels of PUFA have been
found in brain content, red blood cells and skin fibroblast
among patients with schizophrenia, compared with a
healthy population [13,16]. Results from a review of sev-
eral randomized clinical trials of PUFA treatment of
schizophrenia were inconclusive, although, it seems that
supplementation of especially EPA to these patients may
have a positive effect on their schizophrenic symptoms
[17].
Furthermore, it has been hypothesized that prenatal
vitamin D deficiency is a risk factor for schizophrenia,
supported by the role of this vitamin in cell growth and
differentiation, the excess of winter births in schizophre-
nia (a period when vitamin D levels are low), and
increased births of pre-schizophrenic subjects in urban
areas, where vitamin D deficiency is higher [12,18].
However, to our knowledge, no study has investigated
the association between dietary intake of fish, omega-3
and omega-6 PUFA or vitamin D and the risk of having
positive psychotic symptoms in the general adult popula-
tion.
The main purpose of the present study was to evaluate
the association between the dietary intake of different
fish species, the dietary intake of PUFAs (omega-3 and
omega-6) and vitamin D and the prevalence of positive
psychotic-like symptoms in a population-based study
among Swedish women.
Methods
Study population
Women aged 30-49 years, residing in the Uppsala Health
Care Region in Sweden during 1991 and 1992, form the
source population for this study. Of this source popula-
tion, 96 000 women were randomly selected from four
age strata (30-34, 35-39, 40-44 and 45-49 years) and were
invited to participate in the Swedish component of the
Scandinavian Women's Lifestyle and Health Cohort
[19,20]. The women were asked to fill in a paper ques-
tionnaire, including a food frequency questionnaire
(FFQ), and levels of fish, PUFAs and vitamin D intake
were evaluated. Of those invited, over half decided to par-
ticipate. Thus, 49 261 returned the questionnaires and
were enrolled in the study.
In 2002/2003 a follow-up study was initiated, and
women who had responded to the 1991/1992 question-
naire and who were alive and living in Sweden in October
2002 were contacted. Since 1991/1992, 688 women were
deceased, and 491 women had emigrated. 47 859 women
were invited to complete a web-based questionnaire, and
non-responders received a paper questionnaire. The
overall response rate was 72%, and 34 415 answered the
follow-up questionnaire and levels of psychotic-like
symptoms was measured (outcome under study). A
detailed description of the follow-up study and exposure
assessment has been described elsewhere [21]. The Swed-
ish Data Inspection Board and the regional Ethical Com-
mittee approved the study.
Ratings of positive psychotic-like symptoms
The follow-up questionnaire contained 20 questions on
psychotic-like symptoms, (Additional file 1), constituting
the positive symptoms of the CAPE (Community Assess-
ment of Psychic Experiences) questionnaire, a modified
version of the Peters et al. Delusions Inventory, [PDI;
[22]]; which is based on the 9th edition of the Present
State Examination [23]. The questions are styled in a 'Do
you ever feel/think' fashion in order to study continuous
experiences during life-time. The CAPE tool has proven
to be a stable, valid and reliable self-report instrument for
the measurement of psychotic-like experiences in the
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view-based data [24,25]. The questions were translated
from English into Swedish and back-translated to
increase fidelity to the original scale. Two independent
professional translators did the back-translation, and the
consensus version was tested in a pilot study with 50 sub-
jects.
From the responses to the questions on positive psy-
chotic-like symptoms, a variable was created by catego-
rizing women into three groups (Additional file 1). The
"low level symptoms group" included women with no or
few experiences of psychotic-like symptoms (≤3 "some-
times" and no "almost always" and "often" answers to any
of the questions). The "high level symptoms group"
included women with frequent experiences of psychotic-
like symptoms (≥3 "almost always" or "often" answers).
The "middle level symptoms group" was defined as par-
ticipants not included in the low level or high level
groups.
Diet and lifestyle exposure assessment
The self-administered questionnaire in the parent study
assessed lifestyle variables (smoking history, alcoholic
drinking), anthropometry (height, weight, body mass
index, BMI), medical history (previous diagnosis of major
diseases) and average intake of foods and beverages [19].
Dietary habits during the 6 months preceding the
woman's enrolment in the study were ascertained
through a validated FFQ that covered the frequency of
consumption and quantity of about eighty food items and
beverages [26]. The validity of the fat estimates from the
FFQ assessed using Pearson correlation coefficients
between FFQ data and estimates derived from weighed
food records varied between r = 0.4 and r = 0.5. The
validity of PUFA estimated by means of the FFQ was r =
0.5 in comparison to adipose tissue composition [26]. As
part of the FFQ, the participants reported how often, on
average, they ate salmon-type fish (Baltic herring, her-
ring, or mackerel), white fish (cod, saithe, or pike), caviar,
or shellfish (e.g., shrimp): never-seldom, 1-3 times/
month, 1 time/week, 2 times/week, 3-4 times/week, 5-6
times/week, 1 time/day, 2 times/day or 3 times/day.
The average intake of food items from the FFQ were
converted into average intake of energy and nutrients by
linkage to the database of nutrients created by the Swed-
ish National Food Administration [27]. To estimate the
total intake of omega-3 fatty acids, we summarized the
intake of α-linolenic, EPA, DHA and docosapentaenoic
acids (DPA). We combined EPA, DHA and DPA to esti-
mate the total intake of marine fatty acids. To estimate
the total intake of omega-6 fatty acids, we combined the
intake of arachidonic and linoleic acids. We are aware
that some arachidonic acid (AA) could be found in fish
[27], however, we choose to include those fatty acids that
are dominating in fatty fish into the variable "marine fatty
acids".
AA exists in limited levels in liver, meat and eggs, but
can be metabolized in humans from other fatty acids in
the omega-6 fatty acid family. Linoleic acid is the parent
fatty acid of the omega-6 family, and the main source in a
typical Swedish diet is vegetable oil (such as corn oil, sun-
flower oil, soy oil, rapeseed oil and margarine). α-lino-
lenic acid, the parent fatty acid of the omega-3 family can,
to a limited extent, be converted into EPA, DPA and
DHA. Conventional dietary sources of α-linolenic acid
are rapeseed oil, soy oil, dark green leafy vegetables, flax
seed, walnuts and soy beans. EPA and DHA are mainly
found in fatty fish, with levels that vary by the species of
the fish, environmental factors and geographic area [27].
However, we were not able take environmental factors
and geographic area into account, because the study
questionnaire did not assess the origin of fish, such as the
Baltic Sea or the Atlantic Ocean.
Statistical methods
Among the 34 415 women included in the study, we had
information on dietary intake (parent study) and psy-
chotic-like symptoms for 34 310 women (follow-up
study). Participants with an energy intake outside the first
(2261 kJ/d) and 99th (12 335 kJ/d) percentiles were
excluded from the analysis (n = 687). Thus, a total of 33
623 women were included in the analysis.
Baseline characteristics between the low and the high
level group of psychotic-like symptoms were compared
using a two-sided t-test for equal means for continuous,
normally distributed variables and and χ2-test for cate-
gorical variables. Non-normally distributed variables
were log-transformed to normalize the distribution.
The association between fish, fatty acids or vitamin D
and psychotic-like symptoms was summarized in terms
of relative risk ratios (RRRs) and corresponding 95% con-
fidence intervals, and it was evaluated by energy-adjusted
multinomial logistic regression (polytomous logistic
regression), for example: RRR = P(y = high level group;
fish intake >2/week)/P(y = low level group; fish intake >2/
week)/P(y = high level group; no fish intake)/P(y = low
level group; no fish intake). The category "low level symp-
toms group" (no psychotic-like symptoms) was used as
the reference group. The estimated associations given by
a multinomial logistic regression are relative risk ratios
(RRR). For simplicity of language we abbreviated 'relative
risk ratio' to 'relative risk' (RR). Since, the outcome status
(namely psychotic symptoms) among participants was
unknown at study entry we cannot draw any conclusions
about causality, only about the existence of associations
(negative or positive). Based on the hypothesis under
study we interpreted the RR<1 as a negative association
(for simplicity we refer to it from now on "decreased
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we refer to it from now on as "increased risk").
Nutrient density was calculated by dividing the esti-
mated intake of fatty acids, vitamin D and other nutrients
by the total energy intake (i.e., the multivariate nutrient
density model) [28]. The intake of fatty acids and vitamin
D was categorized into quartiles, with the lowest quartile
as the reference category for comparison. The intake of
individual seafood items was grouped into four categories
(none, 1-3 times per month, 1 time per week and 2 times
per week or more). The total intake of all fish and seafood
was grouped into six categories (none, 1-3 times per
month, once per week, twice per week, 3-4 times per
week and 5 times per week or more).
Age- and energy-adjusted models (with age in 5-year
intervals and total energy intake as a continuous variable)
were fitted, as well as models adjusted for additional
potential confounders, including categories of BMI (< 25,
25-29.9, 30 or more), level of education (0 to 10 years, 10-
13 years, 13+ years), country of birth (Nordic countries or
other countries), smoking (yes, no), and intake of selected
food groups and nutrient densities (fish other than the
main exposure of interest, meat, dairy products, vegeta-
bles, fruits, cereals, refined sugar, alcohol, fatty acids
other than the main exposure of interest, retinol, and
vitamins A, B6, and B12), categorized into quartiles, as
well as rheumatoid arthritis (yes, no), gluten intolerance
(yes, no), diabetes (yes, no), intake of multivitamin sup-
plements (never, occasional, regular). In an additional
analysis of the association between alcohol intake and
psychotic-like symptoms, we categorized women into
never drinkers or drinkers, and used drinkers as the refer-
ence category. The selection of covariates included in the
final multivariate models was based on proportional
(≥10%) change in β-coefficients and previous subject
matter knowledge. We initially tested all covariates, and
those included in the final models were considered to be
important confounding factors for the relation between
the main exposure and psychotic-like symptoms. They
are listed in the table footnotes. We decided not to
include dietary Vitamin D estimates in the final multivar-
iate models as fish is a rich source of vitamin D and could
account for some of the effect of fish on our outcome.
Additionally, there is a high correlation between vitamin
D and omega-3 fatty acids (correlation = 0.77). Statistical
analyses were performed using the STATA version 10.0
Results
Characteristics of study participants
Baseline characteristics of the study participants are pre-
sented in Table 1. The women in the high level group of
psychotic-like symptoms were significantly younger, had
a higher prevalence of overweight and obesity and were
less educated than women with less or no experience of
psychotic-like symptoms. Furthermore, a higher propor-
tion of the women in the middle and high level symptoms
groups had grown up outside of the Nordic countries
than women in the low level symptoms group of psy-
chotic-like symptoms. The RR comparing growing up
outside of the Nordic countries for the middle group and
the high level group compared with the low level group
was 1.7 (95% CI, 1.5-2.0) and 5.6 (95% CI, 4.0-6.8),
respectively. Women with no or few psychotic-like symp-
toms smoked less than women in the middle group and
the high level group. The RR comparing ever smokers to
never smokers, for the middle group and the high level
group compared with the low level group was 1.2 (95%
CI, 1.1-1.3) and 1.5 (95% CI, 1.3-1.7), respectively.
Women in the high level group were more likely to be
never drinkers than women in the low level group, the
multivariate RR, adjusted for smoking, BMI, education
and country of birth, was 1.5 (95% CI, 1.2-1.8). There was
no association between alcohol intake and psychotic
symptoms among women in the middle and low psy-
chotic-like symptoms groups (data not shown). The
remaining dietary intake of different food items and spe-
cific nutrients were similar among the three groups of
women with different levels of positive psychotic-like
symptoms (Table 1).
Dietary intake of fish and risk of positive psychotic-like 
symptoms
The risk of positive psychotic-like symptoms in relation
to estimated dietary intake of fish is shown in Table 2.
The risk of belonging to the high or middle psychotic-like
symptom group compared to the low level group was sig-
nificantly lower among women with a high intake of
white fish (cod/saithe/pike) or total fish and seafood
products. For example, after multivariate adjustment, the
risk of high level psychotic-like symptoms was 53% (95%
CI, 30-69%) lower for women who ate all types of fish and
seafood 3-4 times per week, and 55% (95% CI, 46-68%)
lower for women who ate white fish two times per week,
compared to women who never ate fish and seafood or
white fish (Figure 1). However, there was a J-shaped asso-
ciation between psychotic-like symptoms and fatty fish
(herring/mackerel and salmon-type fish) with the stron-
gest inverse association for intermediate dietary intake
(RR: 0.81, 95% CI, 0.66-0.98), whereas a high intake (RR:
1.90, 95% CI, 1.34-2.70) of fatty fish was associated with
an increased risk of high level psychotic-like symptoms.
In the high level symptoms group compared with the low
level symptoms group, the intake of shellfish 1-3 times
per month was associated with a reduced risk, whereas
the intake of shellfish more than three times per week
was associated with an increased risk. The latter result
did not remain significant after multivariate adjustment
(Table 2).
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questionnaire data in the women's lifestyle and health study
Positive psychotic-like symptomsa
Low level group Middle level group High level group
N = 18 411 N = 14 395 N = 817
Characteristics (55%) (43%) (2.4%)
Age b, years, mean (SD) 52 (6) 51 (6) 50 (6)
BMI, kg/m2, mean (SD) 23 (3.4) 23 (3.8) 24 (4.0)
BMI, kg/m2, No. (%)
< 25 normal weight 13 381 (73) 10 030 (70) 506 (62)
25-29.9 overweight 3 697 (20) 3005 (21) 198 (24)
≥ 30 obese 770 (4) 857 (6) 71 (9)
missing 563 (3) 503 (3) 42 (5)
Education, No. (%)
0-10 years 4 853 (26) 3 829 (27) 235 (29)
11-13 years 6 899 (37) 5 845 (41) 336 (41)
over 13 years 6 342 (34) 4 463 (31) 227 (28)
missing 317 (2) 258 (2) 19 (2)
Country of birth, No. (%)
northern countries 18 060 (98) 13 942 (97) 744 (91)
other countries 318 (2) 427 (3) 68 (8)
missing 33 (0.2) 26 (0.2) 5 (0.6)
Smokers, No. (%)
never 8 111 (44) 5 702 (40) 281 (35)
ever 10 250 (56) 8 656 (60) 534 (65)
missing 50 (0.3) 37 (0.3) 2 (0.2)
Alcohol intake, No. (%)
ever 16 258 (88) 12 614 (88) 668 (82)
never 2 153 (12) 1 781 (12) 149 (18)
Dietary intake, g/day, median (5-95%) of:
fatty fish 7 (0-21) 7 (0-21) 7 (0-28)
meat 76 (26-144) 78 (22-149) 77 (3-167)
dairy products 330 (20-831) 331 (14-850) 320 (4-857)
vegetables 79 (22-177) 79 (21-186) 80 (19-214)
fruit 107 (15-315) 106 (11-311) 102 (7-337)
cereals 125 (47-280) 129 (47-288) 129 (41-299)
saccharides (sugar) 20 (7-44) 20 (7-45) 21 (6-51)
alcohol 2.5 (0-11) 2.4 (0-11) 1.8 (0-12)
marine fatty acidsc 0.27 (0.07-0.6) 0.27 (0.06-0.6) 0.26 (0.05-0.7)
omega-3 fatty acidsd 1.3 (0.6-2) 1.3 (0.6-2) 1.2 (0.6-2)
omega-6 fatty acidse 4.8 (2-8) 4.8 (2-8) 4.7 (2-8)
vitamin D (μg/day) 4.0 (1.8-7.1) 3.9 (1.7-7.2) 3.8 (1.4-7.1)
Total energy intake, kJ/day, 
mean (SD)
6 509 (1 801) 6 626 (1 886) 6 637 (1 986)
Proportion of total energy intake, % from:
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and risk of positive psychotic-like symptoms
The relative risk of positive psychotic-like symptoms by
the level of fatty acids intake is shown in Table 3. After
multivariate adjustment, the intake of omega-6 fatty acids
was significantly associated with a decreased relative risk
of psychotic-like symptoms. In women belonging to the
high level symptoms group, the RRs with increasing
quartiles of omega-6 intake were: 0.67 (95% CI, 0.55-
0.82), 0.66 (95% CI, 0.54-0.81), 0.78 (95% CI, 0.64-0.97).
The results for omega-3 fatty acid and marine fatty acids
(EPA, DHA) had a similar pattern, indicating a reduced
risk of psychotic-like symptoms among women with
intermediate levels of intake. After multivariate adjust-
ment, the risk of high level psychotic-like symptoms for
intake of omega-3 or marine fatty acids was 24% lower in
the third quartile compared to the lowest.
The intake of vitamin D was significantly associated
with a decreased relative risk of both the middle and high
levels of psychotic-like symptoms (Table 4). For example,
after multivariate adjustment, the risk of middle respec-
tive high level psychotic-like symptoms for intake of vita-
min D were respectively 18% and 37% lower in the
highest quartile compared to the lowest quartile of intake.
Discussion
We report here results from the first study that has evalu-
ated the dietary intake of fish, PUFA and vitamin D in
relation to the experience of positive psychotic-like symp-
toms in a large cohort of over 30 000 Swedish women. We
found support for a protective effect regarding the risk of
positive psychotic-like symptoms with high dietary intake
of fish, omega-3 and omega-6 PUFA, as well as of vitamin
D. The associations were J-shaped with the strongest
reduced risk for an intermediate intake of fish or PUFA.
Our findings provide further support for the hypothesis
that an aberration in lipid metabolism may be involved in
the biochemical basis for psychiatric disorders [13]. This
suggestion has earlier been supported by ecological stud-
ies showing that variations in schizophrenia outcome
between countries may be due to differences in the diet
[6,14]. Further evidence for the hypothesis that PUFA is
involved in the etiology of psychiatric disease has been
put forward through the study by Stokes et al. showing a
negative correlation between dietary PUFA intake and
the severity of psychotic symptoms [15], as well as studies
showing that patients with schizophrenia or depression
have lower levels of PUFAs in brain tissue, red blood cells
and skin fibroblasts and with a low intake of fish and
PUFAs [16,29-31]. Finally, supplementation of PUFA,
especially EPA, has been reported to be of possible bene-
fit for patients with schizophrenia [17].
No earlier studies that we are aware of have evaluated
the relationship between adult vitamin D levels and psy-
chotic symptoms. Our findings indicated a protective
effect of vitamin D for the risk of psychotic-like symp-
toms. Prenatal vitamin D deficiency has been proposed to
be a risk factor for the development of schizophrenia [12].
Results from the Northern Finland 1966 Birth Cohort
showed that vitamin D supplementation during the first
year of life was associated with a reduced risk of schizo-
phrenia in males, but not in women [32]. However, a
small pilot study of maternal vitamin D levels in archived
prenatal sera, showed no decrease in prenatal vitamin D
in subjects who later developed schizophrenia [33]. It has
been hypothesised that vitamin D insufficiency could
account for some of the increased risk of schizophrenia
observed among dark-skinned immigrants moving to
countries with less sun exposure [12]. Vitamin D is to a
large extent metabolized in the body through sun expo-
sure, and people with dark skin need more sun exposure
to maintain adequate blood levels. Our results of a pro-
tective effect of vitamin D intake must be considered as
rough, since we only measure the dietary intake of vita-
min D. A more complete picture of the vitamin D status
could have been supplied through vitamin D levels in
• fat 31 31 31
• protein 16 16 16
• carbohydrate 51 51 51
• alcohol 1 1 1
a Participants categorized into levels of psychotic-like symptoms; low, middle, high (see methods section)
b Age at the completeness of the follow-up questionnaire
c Sum of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid
d Sum of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid and α-linolenic acid
e Sum of arachidonic and linoleic acids
Table 1: Selected baseline characteristics by categories of psychotic-like symptoms, of 33 623 participants with 
questionnaire data in the women's lifestyle and health study (Continued)
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absorption of dietary vitamin D is generally high at all
stages of life [34], but serum levels also depend on the
endogenous production of vitamin D due to sun exposure
which is subject to seasonal variations. Thus, the correla-
tion between vitamin D intake and serum levels may vary.
However, Burgaz et al. recently reported that 2-3 weekly
servings of fatty fish increased 25(OH)D by 45% in a pop-
ulation of Swedish women [35]. Our results of the protec-
tive effect of fatty fish could in part be due to the content
of vitamin D. While the epidemiological evidence linking
low prenatal vitamin D and schizophrenia remains incon-
clusive, rodent models have provided compelling evi-
dence about the role of vitamin D deficiency for brain
Table 2: Relative risk of positive psychotic-like symptoms in relation to estimated dietary intake of fish
Dietary intake Positive psychotic-like symptomsa
Low level group Middle level group High level group
Energy adjusted Multivariateb Energy adjusted Multivariateb
No. No. RR 95% CI RR 95% CI No. RR 95% CI RR 95% CI
Salmon-type fish and herring/mackerel, frequency
never 5 027 Ref. 4 090 252
1-3 per month 5 962 4 547 0.93 0.88-0.98 0.99c 0.93-1.05 216 0.72 0.60-0.86 0.81c 0.66-0.98
1 per week 6 381 4 727 0.90 0.85-0.95 0.99c 0.93-1.05 248 0.76 0.64-0.90 0.92c 0.75-1.12
≥2 per week 494 526 1.27 1.12-1.43 1.32c 1.15-1.51 48 1.74 1.26-2.39 1.90c 1.34-2.70
Cod/saithe/pike, frequency
never 1 289 Ref. 1 136 96
1-3 per month 7 009 5 311 0.85 0.78-0.93 0.89d 0.82-0.98 322 0.62 0.49-0.78 0.70d 0.55-0.89
1 per week 8 096 6 185 0.84 0.77-0.92 0.87d 0.80-0.95 270 0.43 0.34-0.55 0.46d 0.36-0.59
≥2 per week 1 470 1 258 0.93 0.83-1.04 0.90d 0.81-1.01 76 0.69 0.50-0.93 0.57d 0.41-0.79
Shellfish, frequency
never 4 540 Ref. 3 815 243
1-3 per month 11 075 8 219 0.88 0.84-0.93 0.90e 0.85-0.95 412 0.70 0.59-0.82 0.78e 0.66-0.93
1 per week 1 893 1 453 0.91 0.84-0.99 0.92e 0.84-1.00 78 0.77 0.59-1.00 0.84e 0.64-1.11
≥2 per week 356 403 1.34 1.15-1.55 1.28e 1.09-1.49 31 1.70 1.16-2.48 1.42e 0.94-2.14
All fish and seafood, frequency
never 533 Ref. 476 44
1-3 per month 1 131 996 0.96 0.82-1.11 0.96 f 0.83-1.12 84 0.87 0.60-1.27 0.89 f 0.61-1.31
1 per week 7 025 5 450 0.83 0.73-0.95 0.86 f 0.76-0.89 290 0.48 0.34-0.67 0.51 f 0.36-0.71
2 per week 7 215 5 261 0.77 0.68-0.88 0.82 f 0.71-0.93 264 0.42 0.30-0.58 0.45 f 0.32-0.64
3-4 per week 1 987 1 668 0.88 0.77-1.02 0.93 f 0.80-1.07 80 0.45 0.31-0.66 0.47 f 0.31-0.70
>5 per week 520 541 1.09 0.92-1.30 1.13 f 0.94-1.35 55 1.19 0.78-1.81 1.12 f 0.72-1.74
a Participants categorized into levels of psychotic-like symptoms; low, middle, high (see methods section)
b In the multivariate analysis presented, we initially tested the effects of adjusting also for BMI, level of education, country of birth, smoking, 
dietary intake of meat, dairy products, fruits, cereals and refined sugar, rheumatoid arthritis, gluten intolerance, diabetes and multivitamin 
supplement. However, none of these covariates change the estimates substantially, and was therefore not included in the final multivariate 
model
c Adjusted for age, total energy intake and dietary intake of vegetables, vitamin B12, alcohol, cod-type fish and shellfish
d Adjusted for age, total energy intake and dietary intake of vegetables, vitamin B12, alcohol, salmon-type fish and shellfish
e Adjusted for age, total energy intake and dietary intake of vegetables, vitamin B12, alcohol, salmon-type fish and cod-type fish
f Adjusted for age, total energy intake and dietary intake of vegetables, vitamin B12 and alcohol
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Page 8 of 13development like larger lateral volumes [36], subtle mem-
ory dysfunction and altered attention processing [37]
which have implications for neuropsychiatric disorders.
Unexpectedly, the intake of fatty fish (salmon, herring
and mackerel) or shellfish more than twice a week
increased the risk of being in the group with the highest
level of psychotic-like symptoms. This puzzling finding
may be due to unknown or known unhealthy constituents
of fatty fish. For instance, environmental pollutants such
as polychlorinated biphenyls (PCB) and dioxins are
known to accumulate in fatty fish [38]. Another possible
explanation may be that the frequent intake of fish and
PUFA may be advantageous in lower doses but disadvan-
tageous in higher doses. Reports by Mischoulon et al. and
Peet & Horrobin suggest that there might be such a thera-
peutic window for DHA and EPA regarding their protec-
tive role for schizophrenia or depression [39-41].
Significant higher levels of DHA have been found in red
cell membranes of un-medicated schizophrenic patients
compared to healthy control subjects [42]. Furthermore,
our findings of a more pronounced protective effect of
omega-6 fatty acids than for omega-3 fatty acid are in
agreement with the results from an EPA supplementation
study in schizophrenia presented by Horrobins et al. [43].
This study surprisingly found that the effect of intermedi-
ate doses of EPA increased the levels of AA (an omega-6
PUFA) in the membrane of red cells, whereas higher
doses of EPA did not, and the EPA-induced rise in AA
was associated with a clinical improvement. The respec-
tive biological effects of omega-3 fatty acids and omega-6
fatty acids on the etiology of psychiatric symptoms could
very well differ and the balance between the intakes of
these fatty acids might be of importance. A high intake
ratio of omega-3:omega-6 fatty acids favor omega-3 fatty
acid metabolism. For example, high intake of omega-3
fatty acids partly replaces omega-6 fatty acids incorpora-
tion into membrane phospholipids and omega-3 fatty
acids have a higher affinity than omega-6 fatty acids for
several enzymes [44]. It has been proposed that the ratio
of omega-3:omega-6 fatty acids might be more important
in inhibiting the development of several diseases, includ-
ing cancer, inflammatory and heart diseases [45,46]. We
find no support for this in our results, since, the effect of
omega-3:omega-6 fatty acids on psychotic-like symptoms
were almost similar to those of omega-3 fatty acids. How-
Figure 1 Relative risk of positive psychotic-like symptoms in relation to estimated dietary intake of all fish and seafood 4. 1Relative risk (RR) 
and 95% confidence interval evaluated by multinomial logistic regression, adjusted for age, total energy intake and dietary intake of vegetables, vita-
min B12 and alcohol. 2 The group with no or low level of psychotic symptoms was used as reference group. 3 Participants categorized into levels; no/
low, middle, high frequency of psychotic-like symptoms. 4 Total intake of all fish and seafood were grouped into six categories; none, 1-3 times per 
month, once per week, twice per week, 3-4 times per week and 5 times per week or more.
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Page 9 of 13Table 3: Relative risk of positive psychotic-like symptoms in relation to estimated dietary intake of fatty acids
Dietary intake g/
day·MJ
Positive psychotic-like symptoms a
Median Interquintile 
range
Low level group Middle level group High level group
Energy adjusted Multivariateb Energy adjusted Multivariateb
Marine fatty acidsc No. No. RR 95% CI RR 95% CI No. RR 95% CI RR 95% CI
0.016 (0.00-0.02) 4478 Ref. 3637 237
0.030 (0.02-0.04) 4606 3587 0.94 0.89-1.00 0.97 d 0.91-1.03 177 0.71 0.58-0.87 0.75 d 0.61-0.92
0.050 (0.04-0.06) 4733 3538 0.91 0.86-0.97 0.96 d 0.90-1.02 176 0.69 0.57-0.85 0.76 d 0.61-0.93
0.070 (0.06-0.80) 4594 3633 1.00 0.94-1.06 1.05 d 0.98-1.13 227 0.96 0.80-1.16 1.05 d 0.85-1.29
Omega-6 fatty acidse
0.6 (0.1-0.7) 4408 Ref. 3712 261
0.7 (0.6-0.8) 4709 3513 0.88 0.82-0.93 0.88 f 0.83-0.94 182 0.64 0.53-0.78 0.67 f 0.55-0.82
0.8 (0.7-0.8) 4670 3582 0.90 0.85-0.96 0.91 f 0.86-0.97 173 0.62 0.51-0.75 0.66 f 0.54-0.81
0.9 (0.9-2.1) 4624 3588 0.92 0.86-0.98 0.93 f 0.86-0.99 201 0.73 0.60-0.88 0.78 f 0.64-0.97
Omega-3 fatty acidsg
0.14 (0.02-0.17) 4444 Ref. 3663 252
0.18 (0.17-0.20) 4613 3628 0.95 0.89-1.01 0.98 b 0.92-1.04 175 0.66 0.54-0.81 0.73 h 0.60-0.89
0.21 (0.20-0.22) 4736 3512 0.90 0.84-0.96 0.95 b 0.89-1.01 176 0.66 0.53-0.80 0.76 h 0.62-0.94
0.26 (0.22-0.93) 4618 3592 0.96 0.90-1.02 1.02 b 0.95-1.09 214 0.83 0.69-1.00 1.00 h 0.82-1.23
a Participants categorized into levels of psychotic-like symptoms; low, middle, high (see methods section)
b In the multivariate analysis presented, we initially tested the effects of adjusting also for BMI, level of education, country of birth, smoking, 
dietary intake of meat, dairy products, fruits, cereals and refined sugar, rheumatoid arthritis, gluten intolerance, diabetes and multivitamin 
supplement. However, none of these covariates change the estimates substantially, and was therefore not included in the final multivariate 
model
c Sum of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid
d Adjusted for age, total energy intake and dietary intake of vitamin B12, alcohol and dietary intake of fat other than eicosapentaenoic acid, 
docosahexaenoic acid and docosapentaenoic acid
e Sum of arachidonic and linoleic acids
f Adjusted for age, total energy intake and dietary intake of vitamin B12, alcohol and dietary intake of other than omega-6 fatty acids
g Sum of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid and α-linolenic acid
hAdjusted for age, total energy intake and dietary intake of vitamin B12, alcohol and dietary intake of other than omega-3 fatty acids
ever, the mechanisms of action and protective abilities of
PUFA could differ between different diseases.
The non-linearity in the association might seemingly
argue against a possible causal relationship. However, the
associations with dietary components and health are
often non-linear with advantageous effects of a balanced
nutrition [47-50]. We have no baseline measure of symp-
tom levels to further elucidate causality between different
levels of intake of fatty fish or shellfish and the risk of pos-
itive psychotic-like symptoms. However, keeping the
prevalence figures for psychotic disorders in mind, rather
few participants in our population sample are likely to
have a disorder, which may diminish the problem of
reversed causality related to psychotic diagnosis or medi-
cation.
In our study, the definition of psychotic-like symptoms
was based on self-reported frequency of psychosis-like
experiences. The classification of women into three
groups with different levels of symptoms (low, middle
and high) was based on predefined, but arbitrary cut-offs
from the self-reported answers to the CAPE question-
naire. We acknowledge the limitation that the scale have
not been used earlier in Sweden and validated in the
Swedish population. Among women in the group with
the highest level of psychotic-like symptoms, overweight,
obesity and smoking were more common, and this group
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Page 10 of 13also contained more women who had migrated to Swe-
den. These characteristics are often seen in patients with
psychotic disorders [51-53]. Based on the sum population
prevalence of schizophrenia and other psychoses in mid-
dle-aged women [54], we might expect that 2-3% of the
study participants would cross the boundaries to clini-
cally valid syndromes. Our high level symptoms group
consisted of 840 persons or about 2.5% of the whole study
group. The CAPE measures of psychosis are strongly cor-
related with measures of general psychopathology,
including depression. The association between the posi-
tive and the depressive dimension in CAPE, which we
unfortunately could not include for practical reasons, is
fairly low when distress associated with positive symp-
toms is held constant (r = 0.25; Stefanis et al., 2002 [1]).
Thus, there are reasons to believe that the dimension of
positive symptoms is an independent dimension.
In terms of generalisability of our results it is relevant to
compare the levels of dietary intake of PUFAs and vita-
min D in our cohort to other populations. The contribu-
tion of dietary intakes of PUFAs to total dietary fat is
comparable to other Western cohorts [55]. The quotient
omega-6 PUFA/omega-3 PUFA was 4:1 in this study, and
this value is comparable to other European cohorts
[56,57], but lower than that has been reported for US
populations (Food and Nutrition Board. Dietary Refer-
ence Intakes for macronutrients Institute of Medicine,
National Academic Press, Washington: 2005). The
dietary intake of vitamin D in this cohort is comparable
to several other European populations [58]. It is relevant
to note that in Sweden low-fat dairy products and marga-
rines are fortified with vitamin D. Otherwise the dietary
intake of vitamin D would be lower. Furthermore, men
were not included in the study and there is gender differ-
ence in the prevalence of psychosis [59]. However psy-
chotic-like experiences in the general population might
be more equally distributed among women and men [60].
The strengths of our study include its thorough diet
data design and large sample size. The ethnic homogene-
ity of our study population reduces the risk of confound-
ing by unmeasured factors, both genetic and
environmental. We were able to adjust for smoking, BMI,
migration, education and alcohol that could confound
our associations between diet and psychotic-like symp-
toms. We had no information about socioeconomic sta-
tus, but the adjustment for education, which is strongly
associated with socioeconomic status, did not change the
estimates. Still, we cannot rule out that there are
unknown confounders that we have not been adjusted
for, for example drugs influencing levels of serum lipids
or family history of psychiatric illness. If the proportion
of non-urbanized participants was high in the study pop-
ulation this could have confounded our results, neverthe-
less this is not the case in the Swedish population.
Misclassification of fish and PUFA or vitamin D intake
due to measurement error associated with the food fre-
quency questionnaire is unavoidable, but given the study
design likely non-differential, and thus attenuating any
true association. It is also relevant to note that Hibbeln et
al. reported high correlations (r = 0.7) between the
dietary intake of EPA and DHA and serum levels of EPA
and DHA in subjects with schizophrenia [51], indicating
a good ability to report dietary intake accurately. An
important limitation of this study is that we measured
dietary intake only once, involving misclassification
among those who changed their dietary pattern during
follow-up. However, again some misclassification of
dietary intake cannot be ruled out, such a misclassifica-
tion is likely to be non-differential, and attenuating any
true association. Unfortunately, we do not have informa-
tion about specific vitamin D supplementation. But,
adjustment for multivitamin supplement intake, contain-
ing vitamin D, did not change the estimates. None of the
women in this study reported the use of dietary supple-
ments containing fish oil or PUFA at baseline. Unfortu-
nately, we do not have any information about the use of
such supplements during follow-up. However, according
to national figures from the National Food Administra-
tion, a low number of Swedish women took fish oil sup-
plements (1%) at the time of the study.
We compared a number of characteristics for partici-
pants who completed the questionnaire, both in the par-
ent study and the follow-up study, with those who only
answered the questionnaire in the parent study. Age and
overall dietary intake as well as the intake of fish and fatty
acids did not differ significantly between those who par-
ticipated in the follow-up study and those who did not
(drop-outs). The drop-outs had a slightly higher BMI,
lower education and were more often smokers and born
outside of the Nordic countries. However, our main expo-
sure (fish/fatty acids) did not differ between those who
participated and those who did not participate in the
study.
Conclusions
In conclusion, in this large-scale cohort of Swedish
women we found that a frequent consumption of fish,
omega-3 and omega-6 fatty acids appears to reduce the
risk of positive psychotic-like symptoms. The associa-
tions for fatty fish or shellfish were J-shaped, with the
strongest inverse association for an intermediate dietary
intake, whereas a high intake was associated with a higher
rate of high level psychotic-like symptoms. Interestingly,
we found a lower rate of psychotic-like symptoms with
increasing vitamin D intake. Future studies are warranted
for replication and should evaluate if this is a causal rela-
tionship. There are no current studies that can give real
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Page 11 of 13good answers to the question if dietary deficiency inter-
acts with genetic vulnerability for schizophrenia. Schizo-
phrenia is a multifactorial disorder with strong genetic
vulnerability and the vulnerability might include meta-
bolic aberrations. Further, it would be of interest to study
if dietary aspects are associated with separable latent
dimensions of positive psychotic-like symptoms and if
the associations are valid for men and for other age
groups.
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